NewLink Genetics Competitors and Similar CompaniesClear all
NewLink Genetics's competitors and similar companies include Calithera Biosciences, CytomX Therapeutics, Sirnaomics US and Immodulon Therapeutics.
 NewLink Genetics NewLink Genetics, a biopharmaceutical company, develops therapeutic and diagnostic agents for patients with cancer and infectious diseases. |  Calithera Biosciences Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. |  CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform. |  Sirnaomics US Sirnaomics is a biopharmaceutical company developing oncology therapeutics by using RNA interference (RNAi) technology. |  Immodulon Therapeutics Immodulon Therapeutics is an immuno-oncology company focused on the development of treatments for cancer. | |
Founding Date | Founding Date 1999 | Founding Date 2010 | Founding Date 2008 | Founding Date 2007 | Founding Date N/A |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Private |
Tags | |||||
Locations | Locations Ames, US HQ Austin, US Devens, US | Locations South San Francisco, US HQ | Locations South San Francisco, US HQ | Locations Germantown, US HQ Cambridge, US | Locations Hayes, GB HQ London, GB |
Employees | Employees 2162% decrease | Employees 798% increase | Employees 15815% increase | Employees 3211% decrease | Employees 10 |
Valuation ($) | Valuation ($) 33.2 m | Valuation ($) 29.2 k | Valuation ($) 78 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $230k (FY, 2021) | Revenue (est.) N/A | Revenue (est.) $76.2m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Net income | Net income ($30.4m) (FY, 2021) | Net income ($39.7m) (FY, 2022) | Net income ($17.4m) (FY, 2025) | Net income N/A | Net income N/A |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 45.2m | Total funding raised $ 105m | Total funding raised $ 132.4m | Total funding raised $ 162m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Calithera Biosciences
HQ
South San Francisco, US
Employees
79↑ 8% increase
Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.
View companyCytomX Therapeutics
HQ
South San Francisco, US
Employees
158↑ 15% increase
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.
View companySirnaomics US
HQ
Germantown, US
Sirnaomics is a biopharmaceutical company developing oncology therapeutics by using RNA interference (RNAi) technology.
View companyImmodulon Therapeutics
HQ
Hayes, GB
Employees
10
Immodulon Therapeutics is an immuno-oncology company focused on the development of treatments for cancer.
View company